The recent announcement by the Department of Defense (DoD) to implement a mandatory testosterone screening program for service members, particularly those aged 30 and over, has ignited a complex debate within the medical and military communities. While the stated intention is to bolster service member health and readiness, the program’s broad rollout raises significant questions and potential unintended consequences, particularly given the evolving understanding of testosterone deficiency, its treatment, and the unique health landscape of military personnel.
Unprecedented Initiative Sparks Medical Scrutiny
The decision to mandate testosterone testing across a large segment of the U.S. military is an unprecedented move, prompting a thorough examination of its potential benefits and risks. As a practicing urologist and health outcomes researcher with extensive experience in men’s health and population-level screening, the implications of this initiative are multifaceted. The growing interest in testosterone supplementation, fueled by both legitimate medical concerns and a burgeoning wellness industry, necessitates a cautious approach when considering widespread screening.
Testosterone, a critical sex hormone, plays a vital role in male development, puberty, and is associated with characteristics such as libido and even aggression. Its production is intricately regulated by the hypothalamic-pituitary-gonadal (HPG) axis, a complex interplay of brain and body systems. As men age, testosterone levels naturally decline, a phenomenon often accompanied by symptoms such as increased body fat, reduced bone density, and decreased libido. These age-related changes can sometimes mimic symptoms seen in conditions affecting the HPG axis, such as genetic syndromes or pituitary tumors. Furthermore, lifestyle factors like obesity, sedentary habits, and certain dietary patterns can also contribute to lower testosterone levels.
The Rise of Testosterone Therapy and Market Expansion
The recognition of declining testosterone levels with age has spurred legitimate interest in testosterone supplementation as a means to mitigate some effects of aging and improve energy in older men. However, this interest has, in recent years, been dramatically amplified by a significant surge in testosterone therapy among middle-aged and older men who exhibit testosterone levels below the reference ranges typically observed in younger men, even in the absence of underlying HPG axis disorders.
This expansion has transformed the global market for testosterone therapy. From a modest $18 million in annual sales in the late 1980s, the market has exploded, projected to reach nearly $2 billion by 2025. This dramatic growth has been significantly propelled by direct-to-consumer advertising, online prescribing platforms, wellness communities, and the influence of online personalities. While many individuals receiving testosterone therapy are managed appropriately, concerns exist regarding those who acquire these therapies through loosely regulated online channels, sometimes resulting in dangerously elevated testosterone levels far exceeding normal or safe parameters.
Examining the Risks and Benefits of Testosterone Replacement Therapy
Testosterone replacement therapy (TRT) can offer tangible benefits, including increased muscle mass, enhanced libido, and in some cases, perceived improvements in mood and behavior. However, the medical community’s understanding of its long-term safety profile is still evolving, and TRT is not without significant risks.
A pivotal study, the Testosterone in Older Men with Mobility Limitations (TOM) trial, was prematurely halted in 2010 due to a statistically significant increase in major cardiac events, such as heart attacks and strokes, among participants receiving TRT. More recently, the Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men (TRAVERSE) trial, published in 2023, provided a more nuanced picture. While it did not replicate the increased cardiac event risk observed in the TOM study, indicating TRT was no worse than placebo in this regard, it did reveal a higher incidence of other serious adverse events, including acute kidney injury, atrial fibrillation, and pulmonary embolism, in those undergoing testosterone therapy.
Furthermore, research involving military service members has highlighted specific concerns. Studies conducted on individuals covered by TRICARE, the military’s health insurance program, have indicated higher rates of kidney stones and obstructive sleep apnea among those using testosterone supplementation. While one study within this research also noted a significant improvement in cardiovascular disease outcomes, these findings underscore the need for careful risk-benefit analysis in the military context.
Implications for Service Members: Fertility and Beyond
A critical consideration, particularly for younger service members, is the impact of TRT on fertility. Defense Secretary Pete Hegseth’s announcement that members aged 30 and over will be tested is particularly relevant here, as this age group often includes individuals who may be considering starting families. TRT is known to reduce testicle size and sperm counts, leading both the American Urological Association and the Endocrine Society to caution against its use in men who plan to have children. The guidelines from these prominent medical organizations recommend against routine population-level screening of asymptomatic men for hypogonadism and advise against routine supplementation for younger men with low testosterone levels, a stance that appears to diverge from the DoD’s new directive.
The complexities of testosterone measurement and interpretation also warrant careful attention. Testosterone levels are subject to significant daily fluctuations and can be influenced by various factors. Accurate diagnosis requires measurements to be taken at specific times of day, often with a confirmatory test, and in conjunction with other blood markers, including complete blood counts and other hormone levels, to establish a definitive diagnosis of low testosterone and identify potential underlying causes.
Moreover, individuals considered for TRT must undergo comprehensive screening for pre-existing conditions that could be exacerbated by testosterone supplementation. This includes screening for sleep apnea, high risk for prostate cancer, heart failure or existing heart disease, and symptoms of thrombophilia (elevated red blood cell counts).
The Challenge of Implementation and Monitoring
Once a TRT protocol is initiated, ongoing monitoring is essential to ensure treatment efficacy and to detect potential side effects. The scale of such monitoring across the entire Department of Defense health system presents a formidable logistical and resource challenge. The critical need for personalized monitoring to ensure safety and effectiveness cannot be overstated if this initiative is to be implemented responsibly.
The decision to implement widespread, population-level testing for testosterone levels in U.S. service members represents a novel approach in military medicine, lacking a clear precedent. The success and safety of this program will hinge on its meticulous execution. It must be accompanied by robust patient and population-level monitoring systems to guarantee that the initiative is conducted in a manner that is both safe and appropriate for the health and well-being of military personnel.
The announcement by Secretary Hegseth that individual service members will have the discretion to decide on supplementation if their testosterone levels are found to be low places a significant onus on the decision-making process. To empower service members to make informed choices, they must receive comprehensive counseling regarding the potential risks and benefits of TRT. This counseling should be highly individualized, taking into account each person’s preferences, unique physiological profile, and, crucially, their susceptibility to potential side effects and their expected response to treatment.
The DoD’s foray into mandatory testosterone screening marks a significant departure in how it approaches the health and wellness of its personnel. While the ultimate goal of enhancing readiness and health is laudable, the path forward requires careful navigation of the intricate medical landscape surrounding testosterone. The program’s success will ultimately be measured not just by the number of tests conducted, but by the diligent safeguarding of service member health through comprehensive understanding, rigorous monitoring, and personalized care.
Alexander Cole, M.D., is a board-certified urologist with expertise in men’s health and health outcomes research. His work has focused on the impacts and implementation of screening tests, including among military servicemembers.
STAT’s coverage of health challenges facing men and boys is supported by Rise Together, a donor-advised fund sponsored and administered by National Philanthropic Trust and established by Richard Reeves, founding president of the American Institute for Boys and Men; and by the Boston Foundation. These supporters are not involved in any editorial decisions concerning STAT’s journalism.
Leave a Reply